BigData@Heart’s ultimate goal is to develop a Big Data-driven translational research platform of unparalleled scale and phenotypic resolution in order to deliver clinically relevant disease phenotypes, scalable insights from real-world evidence and insights driving drug development and personalised medicine through advanced analytics. To accomplish this, BigData@Heart will:
Assemble an unparalleled array of big-data sets;
Create a responsive and agile research framework to address the objectives;
Create systems to leverage existing state-of-the-art solutions from different sources to enable combination for high-power identification, harmonisation, access and analysis of distributed data;
Develop and expand on this distributed data for further analysis;
Create novel frameworks for disease definitions based on up-to-date scientific evidence;
Leverage unique database access and big data science expertise to validate (and tweak) the novel frameworks through a number of pilot studies with high and immediate social relevance;
Involve all relevant stakeholders (including policy makers and insurers) to ensure full support for this new framework;
Ensure proper, wide dissemination of the framework and project results, to maximise impact and speed at which the results will be broadly implemented in the EU, and so that they may serve as a template or inspiration for the rest of the world;
Set new and durable standards for cardiovascular big-data science for the next decades.
The project gathers a total of 19 participants from France, Germany. Netherlands, Spain, Sweden, Switzerland, United Kingdom and United States.
INCLIVA is working on the group of definition of diseases associated with heart failure and atrial fibrillation. One of the interesting aspects that was analysed was to compare real world data with the patients included in clinical trials. On the other hand, INCLIVA also participates in the integration of data into the Observational Medical Outcomes Partnership (OMOP) in order to make available the knowledge generated within the project. PRINCIPAL INVESTIGATOR
Prof. Dr. Josep Redón
The research leading to these results has received support from the EU/EFPIA Innovative Medicines Initiative  Joint Undertaking BigData@Heart grant n° 116074.